Small Molecule API Market Projected to Grow Radiantly¬; Asserts MRFR Unleashing Industry Forecast

Pune, India, December , 2017/MRFR Press Release/- Market Research Future published a Cooked research report on “Small Molecule API Market Research Report - Forecast to 2027”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.

Albemarle Corporation (US), ALLERGAN (Ireland), Aurobindo Pharma (India), Cambrex Corporation (US), Dr. Reddy’s Laboratories Ltd. (India), GlaxoSmithKline plc (UK), Lonza (Switzerland), Merck Sharp & Dohme Corp. (US), Mylan N.V. (UK), Novartis AG (Switzerland), Pfizer Inc. (US), Siegfried AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), and Teva Pharmaceutical Industries Ltd (Israel) are some of the prominent players at the forefront of competition in the small molecule API market and are profiled in MRFR Analysis.

Small Molecule API Market - Overview

The small molecule API market is growing mainly due to rising sedentary lifestyle. According to a recent study report published by the Market Research Future, the Small Molecule API market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2027, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2027).

Small molecules are the organic compounds having low molecular weight which is approximately less than 900 Daltons. It includes lipids, monosaccharaides, secondary messengers, other natural products and metabolites, drugs and other xenobiotic. They are distinct from macromolecules such as proteins. Small molecules API sector plays role of paramount importance for the growth of overall pharmaceutical industry. Developing countries are developing awareness about health of their population and are making significant investments in the healthcare and medical services.

Notably, rising research and development expenditure is the primary driver for small molecule API market. In the year of 2016, the R&D expenditure in the Pharmaceutical Industry was EUR 35000 million, suggested by European Federation of Pharmaceutical Industries and Association. According to the Centres for Disease Control and Prevention, the per capita national health expenditures in 2015 was amounted to be USD 9,990 and total national health expenditure was USD 3.2 trillion. It is also reported that out of total national health expenditures in the US, prescription drugs 10.1% share.

Other push factors such as, growing demand for newly developed small molecules drugs, growing trend of outsourcing, and growing pharmaceutical industry in developing nations are also fuelling the growth of the market. Small-molecule drugs accounted for 84% of pharmaceutical industry revenues in 2014. In addition, small-molecule drugs still account for approximately two-thirds of the candidates in the current robust pharmaceutical industry. There has been a significant development in the small molecule API manufacturing in the segments such as oncology, Cardiovascular Diseases, Metabolic disorders. The demand for the small molecule API drugs in such segments in unprecedented.

Despite these drivers, austerity measures in Europe is expected to hinder the growth of the market. Austerity measures in Europe are putting pressures on margins for drug manufacturers. For instance, in the past, Germany has implemented a free price setting mechanism which had led the pharma companies enjoy high prices of patented pharmaceutical products.

Small Molecule API Market - Competitive Analysis

The Small Molecule API market is currently dominated by various players. Due to rising research and development expenditure various existing and new marketers are continuously coming up with advanced products. The global small molecule API market is currently dominated by numerous players.

Pfizer is one of them by holding a strong share in the market. The company is a leading research based bio pharmaceutical organization. Pfizer apply science and our worldwide assets to convey inventive treatments that develop and essentially enhance lives. Pfizer operates in countries like Germany, France, Greece, Korea, Mexico, Russia, Netherland, India, Poland, Turkey, Israel, China and others. On December 23, 2016, Pfizer acquired small molecule anti-infective business of AstraZeneca. It will be a great boost to Pfizer’s existing anti-infective portfolio. The agreement includes the commercialization and development of the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), Zinforo™ (ceftaroline fosamil), the marketed agents Merrem™/Meronem™ (meropenem), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. On June 24, 2016, Pfizer Inc. acquired Anacor Pharmaceuticals, Inc.

Sun Pharmaceutical Industries Ltd. is another renowned market player in small molecule API market. Product portfolio of the company under the category of active pharmaceutical ingredients includes Abiraterone acetate, Acamprosate Calcium, Acitretin, Adapalene, Adefovir Dipivoxil, Alendronate Sodium, Amifostine Trihydrate, and others. In August, 2016, The company announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza®. On July 11, 2016, the company announced the release of InfuSMART in Europe i.e. technology in which oncology products are developed in a ready to administer (RTA) bag.

Report Details @ https://www.marketresearchfuture.com/reports/small-molecule-api-market-763